Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib, Toripalimab, and SOX in Advanced Gastric Cancer
NCT05024812Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2022
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by The First Affiliated Hospital of Zhengzhou University. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05024812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024812.